Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants have?
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants has 43 citations in the OpenAlex counts ScholarIQ stores.
When was Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants published?
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants has 2021 year in the ScholarIQ index.
What is the open-access status of Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants?
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants has closed oa status in the ScholarIQ index.
What is the DOI of Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants?
The DOI for Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants is on the source record.
What is the PMID of Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants?
The PMID for Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants is on the source record.
What is the OpenAlex record for Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants?
The OpenAlex for Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants is on the source record.